Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systolic Hypertension Clear all
Terminated Phase 3 Interventional

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Mobile, Alabama • Tucson, Arizona • Inglewood, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 22, 2026, 9:59 AM EDT
Completed No phase listed Observational

Blood Pressure Change and Outcome

NCT01330004
View directory record Official record
Conditions
Renal Disease, High Blood Pressure
Interventions
Not listed
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 88 Years
Enrollment
12,695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jul 22, 2026, 9:59 AM EDT
Not listed Not applicable Interventional

Clinical Trial to Assess the Effects of Low-fat Dairy on Systolic Blood Pressure

NCT01463085
View directory record Official record
Conditions
Hypertension
Interventions
Low-fat dairy
Other
Lead sponsor
Dairy Research Institute
Other
Eligibility
20 Years to 69 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glen Ellyn, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

NCT00689819
View directory record Official record
Conditions
Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions
Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Behavioral · Drug
Lead sponsor
Wayne State University
Other
Eligibility
35 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

NCT00523549
View directory record Official record
Conditions
Hypertension, Diastolic Dysfunction
Interventions
valsartan, amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
USA, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

NCT00435162
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan 0.25 mg/kg, Valsartan 1.0 mg/kg, Valsartan 4.0 mg/kg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
USA, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Jul 22, 2026, 9:59 AM EDT
Completed No phase listed Observational

Systolic Pressure Intervention Trial Factors Affecting Factors Affecting Atherosclerosis Study

NCT01475747
View directory record Official record
Conditions
Hypertension, Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
12
States / cities
Palo Alto, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jul 22, 2026, 9:59 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Accuracy of Non-Invasive Blood Pressure Measurement in Adults

NCT01183741
View directory record Official record
Conditions
Hypertension, Hypotension
Interventions
Not listed
Lead sponsor
Sotera Wireless, Inc.
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Not applicable Interventional

"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"

NCT01317329
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Hypoxia, Hypercapnia, Sleep Disorders, Obesity, Hypertension, Coronary Artery Vasospasm, Right Ventricular Overload, Left Ventricular Function Systolic Dysfunction, Ventricular Hypertrophy
Interventions
Clinically prescribed CPAP therapy
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Smartphone App-guided Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure

NCT06229873
View directory record Official record
Conditions
Blood Pressure, Vascular Function, Adherence, Treatment
Interventions
App-Based Inspiratory Muscle Strength Training, Clinic-Based Inspiratory Muscle Strength Training
Device
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

NCT00368277
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

NCT00386139
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

NCT00330369
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Not applicable Interventional

A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome

NCT00940966
View directory record Official record
Conditions
Elevated Triglycerides, Systolic Hypertension, Insulin Resistance, Abdominal Obesity
Interventions
standard ADA diet, energy restricted very-low carbohydrate diet, low glycemic diet
Dietary Supplement
Lead sponsor
CAMC Health System
Other
Eligibility
12 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population

NCT00760266
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2011 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

NCT00387517
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Jul 22, 2026, 9:59 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

NCT03821623
View directory record Official record
Conditions
Hypertension, Aging
Interventions
Nicotinamide riboside, Placebo
Drug · Other
Lead sponsor
Douglas Seals
Other
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH

NCT00277875
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
ALT-711 (alagebrium chloride)
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2009 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 4 Interventional Results available

Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren

NCT00441064
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 60 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
19
States / cities
Orangevale, California • Brooklyn Center, Minnesota • Butte, Montana + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension

NCT00302250
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
ALT-711 (alagebrium chloride)
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2006 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension

NCT00350168
View directory record Official record
Conditions
Hypertension
Interventions
valsartan + amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 4 Interventional

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

NCT00185068
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
16
States / cities
Fort Lauderdale, California • Long Beach, California • Roseville, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Jul 22, 2026, 9:59 AM EDT
Terminated Not applicable Interventional

A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension

NCT02895386
View directory record Official record
Conditions
Hypertension, High Blood Pressure
Interventions
ROX Coupler, Sham procedure
Device · Other
Lead sponsor
ROX Medical, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Jul 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

24 Hour Ambulatory Cardiac Oxygen Consumption

NCT05170061
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Valsartan, Nebivolol/valsartan combination
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 22, 2026, 9:59 AM EDT